Improving Quality Control of mRNA Manufacture with Nanopore Sequencing (2025-2028)
Abstract
The mRNA manufacturing industry has grown rapidly to address the worldwide demand for vaccines. However, more than half the time and cost to manufacture an mRNA vaccine is required for quality control, which is currently slow, expensive, and inaccurate. We have developed a streamlined nanopore sequencing test, VAXSeq, that analyses mRNA quality with superior accuracy and at reduced cost and time. This project partners with Oxford Nanopore to validate VAX-seq for use in routine mRNA manufacture. To demonstrate its advantages, we will benchmark VAX-seq against current quality control methods. Whilst we anticipate its adoption across the pharmaceutical industry, the greatest benefit of VAX-Seq will be safer and more effective mRNA vaccines.
